v3.26.1
Revenue Recognition
 6 Months Ended
Jun. 27, 2026
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Our policies for recognizing sales have not changed from those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the sale originated. The Company had product sales to one customer totaling $20,376 and $35,198, representing 13.3% and 12.3% of net sales, primarily in the U.S. reporting segment during the three and six months ended June 27, 2026, respectively. The same customer had product sales of $16,751 and $30,345 representing 11.3% and 11.2% of net sales during the three and six months ended June 28, 2025, respectively.
The following table presents the Company’s net sales disaggregated by major business within each segment as follows:
Three Months EndedSix Months Ended
June 27, 2026June 28, 2025June 27, 2026June 28, 2025
U.S.
Pain Treatments
$72,704 $64,436 $128,861 $117,122 
Surgical Solutions43,585 45,747 86,126 86,591 
Restorative Therapies18,176 18,592 35,923 35,582 
Total U.S. net sales134,465 128,775 250,910 239,295 
International
Pain Treatments
$9,044 $8,872 $16,313 $15,104 
Surgical Solutions6,767 6,969 12,254 11,359 
Restorative Therapies2,932 3,044 5,820 5,778 
Total International net sales18,743 18,885 34,387 32,241 
Total net sales$153,208 $147,660 $285,297 $271,536 
Changes in estimates related to the Company’s most significant U.S. rebate liabilities for products shipped in previous periods represented approximately 2.8% and 3.6% of U.S. segment revenue for the three and six months ended June 27, 2026, respectively, compared with 2.1% and 2.6% for the three and six months ended June 28, 2025, respectively. For the years ended December 31, 2025 and 2024, such changes represented approximately 1.8% and 1.7% of U.S. segment revenue, respectively.